Compare Byrna Technologies Inc (BYRN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Zoetis Inc — how do they compare? Byrna Technologies Inc trades at $3.55 (market cap $80.33M), while Zoetis Inc trades at $75.55 (market cap $31.05B). The key difference: Zoetis Inc is far larger — about 386.5× Byrna Technologies Inc's market cap, and Zoetis Inc pays a 2.86% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | ZTS | |
|---|---|---|
Market Cap | $80.33M | $31.05B |
Sector | Technology | Health |
52-Week High | $27.63 | $156.76 |
52-Week Low | $3.54 | $71.91 |
Enterprise Value | $71.94M | $38.35B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $3.82, down 1.16% today, with a bearish technical signal from moving averages. Recent Q2 2026 results showed a significant miss with a $0.44 EPS loss versus -$0.10 expected, amid a 42.5% revenue decline. The company is undergoing a marketing reset and acquired HERO Defense Systems to expand its product portfolio. Net income margin turned negative at -3.39% for 2026, though gross margin remains strong at 52.51%.
Outlook is cautious due to execution risks in sales turnaround efforts. Analyst consensus is bullish with 71% buy ratings, but near-term challenges in e-commerce traffic and conversion pose headwinds. The stock's valuation appears reasonable with P/S of 0.76, but profitability concerns and ongoing legal investigations present substantial risks for investors.
Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.
Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
